GIP/GLP-1/glucagon triple receptor agonist

Plain-language summaryIntrigue 91 / 100

Retatrutide is a triple agonist activating GLP-1, GIP, and glucagon receptors simultaneously. The glucagon component adds a fat-burning effect on top of the appetite suppression and glucose control of GLP-1/GIP. Phase 3 trials are ongoing for obesity. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel frontier

82/100

Triple GIP/GLP-1/glucagon agonist with extraordinary Phase 2 weight-loss signal, currently the frontier of metabolic peptide research

Look, the GLP-1 era already redrew metabolic pharmacology, and tirzepatide added GIP to that picture. Retatrutide adds the third piece: glucagon receptor agonism. That’s not incremental. Stacking glucagon on top of dual incretin signaling gives you a compound that hits appetite through GLP-1, potentiates insulin dynamics through GIP, and drives hepatic energy expenditure and lipolytic output through glucagon. Three distinct pathways, one weekly injection. The pharmacological rationale is genuinely elegant.

The Jastreboff et al. Phase 2 trial, published in NEJM in 2023, showed 24.2 percent body weight reduction at 48 weeks in the highest-dose arm. That’s not a modest signal. Tirzepatide in SURMOUNT-1 topped out around 20.9 percent at 72 weeks. Retatrutide got further, faster. The dose-response curve is clean, the dropout rates manageable, and the effect on MASH markers adds another dimension the earlier incretins didn’t have. We’re not reading between the lines here, the Phase 2 data is unusually strong.

Mechanism-wise, the glucagon component deserves more attention than it usually gets in lay discussion. Glucagon receptor agonism in isolation would raise glucose, which sounds counterproductive. But in the context of GLP-1 and GIP coadministration, the hepatic energy expenditure and fat oxidation effects dominate while the hyperglycemic risk is substantially blunted. Its a balance thats been validated in rodent models and appears to hold in humans. Whether the hepatic effects specifically drive the MASH signal is still being worked out in ongoing arms of the trial.

What we like here is the research density. Retatrutide is useful as a probe for dissecting the incretin-glucagon axis in ways tirzepatide simply can’t address. You can ask questions about what glucagon receptor activation specifically contributes to metabolic outcomes by comparing the two compounds head-to-head in preclinical models. That’s real bench utility, not just clinical noise. The three-receptor design also opens questions about receptor crosstalk and downstream signaling that single or dual agonists leave on the table.

What we don’t like is the access picture. This is an investigational compound still in trials, not approved, not commercially available outside of study enrollment. Sourcing for preclinical work is achievable but not straightforward, and quality verification matters more here than with mature peptides. The long-term cardiovascular profile and the glucagon safety signal across diverse populations still need the Phase 3 readout to fully settle. But the Phase 2 results are the strongest weight-loss signal any injectable metabolic peptide has produced in a well-designed trial, and the mechanism has serious depth. For anyone working on incretin biology, metabolic regulation, or MASH models, retatrutide is the compound to watch right now.

Novelty: 88
Mechanism promise: 90
In-category differentiation: 88
Evidence quality: 68
Translational signal: 80
Research bench value: 68

Rationale Scores high across novelty, mechanism, and differentiation because adding glucagon receptor agonism to dual incretin pharmacology is genuinely new territory with strong pharmacological rationale, and Phase 2 human data showing 24.2% weight loss at 48 weeks is the strongest single-agent metabolic signal on record. Evidence score is moderated because Phase 3 is ongoing and regulatory status remains unconfirmed.

GIP/GLP-1/glucagon triple receptor agonist

An Eli Lilly investigational triple receptor agonist of GIP, GLP-1, and glucagon receptors with Phase 3 trials in obesity producing 24% weight loss at 48 weeks.

Abstract

Retatrutide (LY3437943) is an investigational triple agonist of the GIP, GLP-1, and glucagon receptors developed by Eli Lilly and currently in Phase 3 trials for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). The compound builds on the GIP/GLP-1 dual agonist tirzepatide platform by adding glucagon receptor agonism, which contributes additional weight loss through hepatic energy expenditure increases and lipolytic effects. Phase 2 obesity trial results published in 2023 showed approximately 24.2 percent weight loss at 48 weeks at the highest dose, exceeding the magnitude observed with tirzepatide. The compound is not yet FDA approved; Phase 3 program is ongoing. Pharmacokinetics: weekly subcutaneous administration; half-life supports once-weekly dosing. The triple agonist class represents the current frontier of metabolic peptide development.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-084Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: GIP/GLP-1/glucagon triple receptor agonist

Retatrutide

Abstract

Read the full monograph